Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98.4M
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
44.5M
-
Shares change
-
+395K
-
Total reported value, excl. options
-
$78.2M
-
Value change
-
-$5.62M
-
Put/Call ratio
-
0.21
-
Number of buys
-
61
-
Number of sells
-
-50
-
Price
-
$1.76
Significant Holders of Poseida Therapeutics, Inc. - Common Stock, par value $0.0001 per share (PSTX) as of Q2 2023
128 filings reported holding PSTX - Poseida Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2023.
Poseida Therapeutics, Inc. - Common Stock, par value $0.0001 per share (PSTX) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 44.5M shares
of 98.4M outstanding shares and own 45.19% of the company stock.
Largest 10 shareholders include FMR LLC (13M shares), Pentwater Capital Management LP (5.98M shares), BlackRock Inc. (5.18M shares), SILVERARC CAPITAL MANAGEMENT, LLC (2.95M shares), VANGUARD GROUP INC (2.59M shares), GEODE CAPITAL MANAGEMENT, LLC (1.22M shares), MILLENNIUM MANAGEMENT LLC (1.14M shares), STATE STREET CORP (1.12M shares), ACADIAN ASSET MANAGEMENT LLC (1.11M shares), and Aisling Capital Management LP (1.04M shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.